ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Limited held its 41st Annual General Meeting on September 11, 2026, via video conferencing to transact ordinary and special business items.
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
Sandu Pharmaceuticals Limited has filed its 41st Annual Report for the financial year 2025-26, including the notice for the upcoming 41st Annual General Meeting.
Sandu Pharmaceuticals announced its 41st Annual General Meeting scheduled for September 11, 2026. The notice includes resolutions for dividend declaration and board appointments.
Sandu Pharmaceuticals Limited filed its quarterly Statement of Deviation or Variation in utilization of funds for the quarter ended June 30, 2026. No deviation or variation was reported.
Sandu Pharmaceuticals Ltd reported revenue from operations of ₹16.4 Cr (-1.8% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q1 FY27.
Sandu Pharmaceuticals scheduled a Board Meeting for August 11, 2026. The meeting will consider the standalone unaudited financial results for the quarter ended June 30, 2026.
Sandu Pharmaceuticals announced the demise of MD Shri Umesh B. Sandu. Consequently, Shri Balram Viswanathan was redesignated as Chairman and MD, and Dr. Neeti Kapre was appointed Independent Director.
Sandu Pharmaceuticals will hold a board meeting on 11 July 2026 to record the MD’s demise and appoint a Managing Director. Trading window is closed for directors.
Sandu Pharmaceuticals filed its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed general regulatory compliance with minor previous reporting delays noted.
Sandu Pharmaceuticals Limited paid a Rs.31,699 penalty to GST authorities in Uttar Pradesh following a detention order for quantity discrepancies in goods. The company accepted the liability on May 6, 2026, leading to the dropping of proceedings. Management stated there is no major financial impact on the company.
Sandu Pharmaceuticals Ltd confirmed it is not classified as a 'Large Corporate' under SEBI's debt-raising framework for FY 2025-26. The company reported zero outstanding and incremental borrowings for the period ending March 31, 2026.
Sandu Pharmaceuticals Ltd reported zero deviation in the utilization of ₹5.34 Crore raised across three tranches of preferential issues. Funds were deployed for plant revamping, machinery upgrades, and working capital. The company confirmed all proceeds for the first two tranches were fully utilized as of March 31, 2026.
Sandu Pharmaceuticals Limited's Board recommended a dividend of Rs. 1 per equity share for FY 2025-26. The dividend is subject to shareholder approval at the upcoming Annual General Meeting. Record and payout dates will be announced later. This move reflects the company's commitment to returning value to its shareholders.
Sandu Pharmaceuticals Ltd reported revenue from operations of ₹16.9 Cr (+19.9% YoY) and net profit of ₹0 Cr for Q4 FY26.
Sandu Pharmaceuticals Ltd reported audited financial results for FY26 and recommended a final dividend of Rs. 1 per share (10%). The board also reappointed M/s Shekhar Joshi & Co as Cost Auditors and Akhil Pai & Co and Uday & Uday Associates as Internal Auditors for FY27.
Sandu Pharmaceuticals Ltd has scheduled a Board Meeting on May 5, 2026. The board will consider approving standalone audited financial results for the quarter and year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until 48 hours after the results announcement.
Sandu Pharmaceuticals Limited disclosed that it does not qualify as a Large Corporate under SEBI norms for the financial year ended March 31, 2026. The company reported zero outstanding long-term borrowings as of the reporting date.
Sandu Pharmaceuticals Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company confirmed that securities received for dematerialisation during the quarter ended March 31, 2026, were processed and listed on the exchange. This is a routine regulatory filing with no material financial impact.